In the 1980s, when Stella Kourembanas, MD, began her career in neonatology, she cared for newborns with pulmonary ...

Discover 7 surprising ways asthma develops in adulthood – from workplace exposures to hormonal shifts. Frequently begins ...

"Today's results are significant as they show for the first time the positive effect of directly switching to Ultibro Breezhaler from other COPD treatments, such as inhaled steroid-containing ...

Obesity worsens asthma severity and responses to medication, yet most doctors fail to address weight management with these ...

US FDA accepts for review GSK’s BLA for depemokimab for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps: London, UK Tuesday, March 4, 2025, 09:0 ...

Specialty pharmacy expands access to an innovative, steroid-free treatment NEW PROVIDENCE, NJ, UNITED STATES, March 3, 2025 /EINPresswire / -- ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

Moreover, 15% of them were taking LAMA or LABA therapies in combination with inhaled corticosteroids (ICS ... company's lead drug candidate into the large COPD market in late 2023 or 2024.

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.